Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Globe Newswire•13/08/2026•16:05 ET
0
Whiz Insights
Successful End-of-Phase 2 meeting with FDA supports advancement of tegoprubart into a global Phase 3 kidney transplantation trial, on track to initiate in late 2026
Long-term Phase 2 BESTOW data presented at ATC 2026 demonstrated sustained higher kidney function and improved patient-reported outcomes with tegoprubart compared with tacrolimus
Get started
Create a free account to read the full story.